Validation of Differential Serum Levels for Five Minerals in South American Gallstone Patients With and Without Gallbladder Cancer (METALS)
Validation of the Association Between the Abundance of Three Bacterial Genera in Stool Samples and the Risk of Gallbladder Cancer in South American Patients With Gallstones
연구 개요
상세 설명
Gallbladder cancer (GBC) is a highly lethal malignant tumour characterised by a low global incidence, but with a disproportionately high prevalence among indigenous populations in the Americas. The absence of specific symptoms and validated early detection tools often leads to late diagnosis and poor prognosis. To date, no biomarkers have been established for the early detection of GBC.
Minerals and metals play a fundamental role in a wide range of biological processes, and both their excess and deficiency - in the wrong compartment or at the wrong time - can disrupt internal homeostatic balance. It has been proposed that such dysregulation is a relevant factor in carcinogenesis, operating through mechanisms including oxidative stress, DNA damage, and immune dysregulation. Although altered mineral profiles have been described in GBC, and several elements have been proposed as potential risk biomarkers, these findings remain largely exploratory and lack consistent validation in independent cohorts, particularly in populations with a high incidence of GBC.
In our previous research, we quantified the serum concentrations of more than 50 metals and minerals in 240 South American patients (120 with GBC and 120 with gallstones) from the EULAT Eradicate GBC study, of whom more than 30 met strict quality control criteria (e.g., concentrations above the lower limit of detection in at least 95% of samples). We observed that serum concentrations of aluminium (Al) and copper (Cu) were elevated, whilst those of sulphur (S), zinc (Zn) and bromine (Br) were reduced, in serum samples from patients with GBC compared with patients with gallstones.
The aim of this study is to validate the differences in the concentrations of these five minerals using an independent set of South American serum samples (n=115 patients with GBC and n=115 patients with gallstones).
Serum samples will be digested and analysed by inductively coupled plasma mass spectrometry (ICP-MS) on an Agilent 7850 instrument, using indium (In) as an internal standard for signal normalization. More than 50 minerals and metals will be quantified per sample. Based on preliminary data, it is expected that approximately 30 analytes will pass all quality filters and be retained for statistical analysis.
Metal concentration data will be analysed using R. Overall mineral/metal profiles will be assessed through principal component analysis to identify samples with atypical concentration patterns. Analytes with concentrations below the lower limit of detection in more than 5% of samples, or with a median absolute deviation not exceeding the detection threshold, will be excluded from further analyses. To validate the five previously identified associations, metal concentrations will be compared between patients with GBC and patients with gallstone disease using univariate and multiple robust logistic regression, adjusting for potential confounding factors and correcting probability values for multiple comparisons using the Bonferroni method.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Heidelberg, 독일
- Statistical Genetics Research Group, Institute of Medical Biometry, University of Heidelberg
-
-
-
-
-
Cochabamba, 볼리비아
- Complejo Hospitalario Viedma
-
Cochabamba, 볼리비아
- Hospital del Norte
-
Cochabamba, 볼리비아
- Hospital Obrero No. 2 (Caja Nacional del Seguro Social)
-
Cochabamba, 볼리비아
- Instituto Gastroenterológico
-
Cochabamba, 볼리비아
- Instituto Oncológico Nacional
-
-
-
-
-
Arica, 칠레
- Hospital Clínico de Magallanes
-
Arica, 칠레
- Hospital Regional de Arica
-
Concepción, 칠레
- Hospital Regional de Concepción
-
Port Montt, 칠레
- Hospital De Puerto Montt
-
Rancagua, 칠레
- Hospital Regional de Rancagua
-
Santiago, 칠레
- Hospital San Juan de Dios
-
Santiago, 칠레
- Hospital Sótero del Río
-
Santiago, 칠레
- Hospital Clínico Universidad de Chile
-
Santiago, 칠레
- Clínica Alemana de Santiago
-
Santiago, 칠레
- Hospital Padre Hurtado
-
Santiago, 칠레
- Hospital Barros Luco
-
Santiago, 칠레
- Hospital del Salvador
-
Santiago, 칠레
- Fundación Arturo López Perez (FALP)
-
Santiago, 칠레
- Hospital El Pino
-
Santiago, 칠레
- Hospital San Borja
-
Talca, 칠레
- Hospital Regional de Talca
-
Temuco, 칠레
- Clínica Alemana de Temuco
-
Temuco, 칠레
- Hospital Regional de Temuco
-
Temuco, 칠레
- Complejo Asistencial Padre Las Casas
-
-
-
-
-
Arequipa, 페루
- Hospital Goyoneche
-
Arequipa, 페루
- Hospital Honorio Delgado
-
Arequipa, 페루
- Instituto Regional de Enfermedades Neoplásicas del Sur (IREN Sur)
-
Juliaca, 페루
- Clínica Monte Sinaí
-
Juliaca, 페루
- Hospital Base III- La Capilla ESSALUD
-
Lima, 페루
- Instituto Nacional de Enfermedades Neoplásicas (INEN)
-
Puno, 페루
- Hospital Regional Manuel Nuñez Butrón
-
Trujillo, 페루
- Instituto Regional de Enfermedades Neoplásicas del Norte (IREN Norte)
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Patients with gallstones and cancer-free OR - Patients with gallbladder cancer
Exclusion Criteria:
- Patients younger than 18 years
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
South American patients with gallbladder cancer
|
Pathological examination of the gallbladder after cholecystectomy
|
|
South American patients with gallstones
with no evidence of gallbladder cancer upon pathological examination of the gallbladder after cholecistectomy
|
Pathological examination of the gallbladder after cholecystectomy
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Serum concentrations of five minerals among South American gallstone patients with and without gallbladder cancer
기간: Baseline
|
Baseline
|
공동 작업자 및 조사자
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
IPD 공유 액세스 기준
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .